Key Takeaways:
GeneDx Holdings shares plunged 49% on May 5 after a Q1 2026 earnings miss that included a tenfold increase in net loss.
"We're investigating whether GeneDx may have intentionally or recklessly misled investors about key changes in its product mix that have dramatically reduced their growth expectations," Reed Kathrein, the Hagens Berman partner leading the investigation, said.
The company's average reimbursement rate fell about $200 short of the $3,750 level management had said in February would be flat for 2026, blaming an adverse shift toward genome tests whose ARR was half that of exome. GeneDx also cut its full-year 2026 revenue guidance by 12% and lowered exome and genome revenue growth expectations to "at least 20%" from the 33% to 35% range conveyed five weeks into the quarter.
The single-day selloff erased more than $900 million from GeneDx's market capitalization. The national shareholder rights law firm opened an investigation into whether the company violated federal securities laws.
GeneDx operates a data-driven clinical diagnostics business focused on rare and ultra-rare disease testing, deriving revenue primarily from billing payers for genome and exome sequencing tests. The company had emphasized the durability of its ARR and a "consistent trend of acceleration" in genome and exome growth, according to prior investor communications cited by Hagens Berman.
The stock's move lower has prompted the firm to urge investors who suffered significant losses to contact them. Under the SEC Whistleblower program, individuals with non-public information may receive rewards totaling up to 30 percent of any successful recovery.
The decline puts GeneDx shares at their lowest level since the company's growth narrative shifted, testing investor confidence in the genomic diagnostics sector. Investors will watch for any further disclosures from the company or updates from the investigation in coming weeks.
This article is for informational purposes only and does not constitute investment advice.
